MiR-133a is downregulated in non-small cell lung cancer: a study of clinical significance

Li, Dong; Zhang, Daniel Xin; He, Rong‐Quan; Tang, Rongjiang; Li, Ping; He, Qiancheng; Chen, Gang

doi:10.1186/s40001-015-0139-z

Cited by 33 publications

(37 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiRNAs can regulate several biological processes (BPs), including growth, differentiation, proliferation, apoptosis necrosis, and invasion by targeting sets of messenger RNAs. [18][19][20][21] Reports have demonstrated that miRNAs play a potentially significant role in identifying markers for the diagnosis, prognosis, and treatment strategies for numerous human cancers, including oral cancer, 22 breast cancer, 23 pancreatic cancer, 24 testicular cancer, 25 and lung cancer, [26][27][28][29][30][31] among others.…”

Section: Introductionmentioning

confidence: 99%

Clinical value of miR-145-5p in NSCLC and potential molecular mechanism exploration: A retrospective study based on GEO, qRT-PCR, and TCGA data

et al. 2017

Self Cite

View full text Add to dashboard Cite

MicroRNAs have been reported to be involved in various biological processes. Here, we performed a systematic analysis to explore the clinical value and potential molecular mechanism of miR-145-5p in non-small cell lung cancer. First, a meta-analysis was performed with eligible literature, followed by microRNA microarrays in the Gene Expression Omnibus database, to verify the diagnostic and prognostic values of miR-145-5p. A cohort of 125 clinical paired non-small cell lung cancer samples was next used to detect the level of miR-145-5p and to explore the relationship of miR-145-5p with clinicopathological parameters. The Cancer Genome Atlas database was additionally applied to investigate the role of miR-145-5p in non-small cell lung cancer. The potential targets of miR-145-5p were predicted using 12 online prediction databases to explore the prospective molecular mechanism of miR-145-5p in non-small cell lung cancer. The expression of miR-145-5p in non-small cell lung cancer was significantly lower than that in healthy tissues. And miR-145-5p tended to show better diagnostic performance in lung squamous cell carcinoma than in lung adenocarcinoma. Furthermore, the expression of miR-145-5p was closely associated with lymph node metastasis in non-small cell lung cancer. Gene ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathway analysis revealed that the target genes were mainly enriched with enzyme-linked receptor protein signaling pathways, SH3 domain binding, cell leading edge, and adherens junction. The protein-protein interaction network showed that eight hub genes (SMAD4, SMAD2, IRS1, FOXO1, ERBB4, NRAS, ACTB, and ACTG1) might be the key target genes of miR-145-5p in non-small cell lung cancer. The information we obtained might offer new perspectives for clinical diagnosis and treatment for non-small cell lung cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical value of miR-145-5p in NSCLC and potential molecular mechanism exploration: A retrospective study based on GEO, qRT-PCR, and TCGA data

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…The evaluated mean ±sd 2−Δcq mir-133a expression by qrT-pcr in Nsclc tissues was 2.0108 ± 1.3334, significantly lower than that of the adjacent non-cancerous tissue 3.6430 ± 2.2625. mir-133a expression was 1.8035 ± 1.3079 in Nsclc patients with lymph node metastasis than in those without 2.0787 ± 1.3777. The expression was also negatively correlated to tumour size, TNm stages and eGFr protein expression 150 . an example of the one microrNa targeting more genes provides the experiments revealing the biological functions of mir-33a.…”

Section: Mirnas Involved In Lymph Node Metastasismentioning

confidence: 90%

The role of microRNA in metastatic processes of non-small cell lung carcinoma

Pastorkova¹,

Škarda²,

Andel³

2016

BIOMED PAP

View full text Add to dashboard Cite

Background. MicroRNAs are small non-coding one-stranded RNA molecules that play an important role in the posttranscriptional regulation of genes. Bioinformatic predictions indicate that each miRNA can regulate hundreds of target genes. MicroRNA expression can be associated with various cellular processes leading to the metastasis of malignant tumours including non-small cell lung carcinoma. This review summarizes current knowledge on the role of microRNAs in NSCLC metastasis to the brain and lymph nodes. Methods. A search of the NCBI/PubMed database for publications on expression levels and the mechanisms of microRNA action in NSCLC metastasis. Results and Conclusion. Dysregulation of microRNAs in NSCLC can be associated with brain and lymph node metastasis. There are differences in microRNA expression profiling between NSCLC with and without metastases but it is currently not possible to reliably predict the site of metastasis in NSCLC. Based on data from RNAmicroarrays, bioinformatics analysis is able to predict the target genes of highlighted microRNAs, providing us with complex information about cancer cell features such as enhanced proliferation, migration and invasion. Such microRNAs may then be knocked-down using siRNAs or substituted with miRNA mimics. RNA microarray profiling may thus be a useful tool to select up-or down-regulated microRNAs. A number of authors suggest that microRNAs could serve as biomarkers and therapeutic targets in the treatment of NSCLC metastasis.

show abstract

“…[15][16][17]27,28 The internal reference was the combination of miR-191 and miR-103, whose stability had been verified previously. [15][16][17]27,28 Sequences of the miRNAs in this study were as follows: AACUGU UUGCAGAGGAAACUGA (miR-452-5p); CAACGGAA UCCCAAAAGCAGCU (miR-191); and AGCAGCAUUG UACAGGGCUAUGA (miR-103). The miR-452-5p expression was computed with the formula 2 −Δcq .…”

Section: Quantitative Real-time Polymerase Chain Reaction Detection Omentioning

confidence: 99%

“…11,12 Many studies have reported the role of miRNA in the development of LUAD and its important value in the diagnosis, treatment, and prognosis of this disorder. [13][14][15][16][17] MiR-452-5p, previously also named as miR-452, is an RNA molecule obtained by modification of the 5′ end of pre-miR-452. Previous studies have reported that miR-452-5p expressions in different neoplasms are distinct, which is upregulated in urinary tract epithelial tumors, esophageal cancer, and liver cancer, [18][19][20] but downregulated in breast cancer, prostate cancer, and glioma.…”

Section: Introductionmentioning

confidence: 99%

Clinical value of miR-452-5p expression in lung adenocarcinoma: A retrospective quantitative real-time polymerase chain reaction study and verification based on The Cancer Genome Atlas and Gene Expression Omnibus databases

et al. 2017

Self Cite

View full text Add to dashboard Cite

The role and mechanism of miR-452-5p in lung adenocarcinoma remain unclear. In this study, we performed a systematic study to investigate the clinical value of miR-452-5p expression in lung adenocarcinoma. The expression of miR-452-5p in 101 lung adenocarcinoma patients was detected by quantitative real-time polymerase chain reaction. The Cancer Genome Atlas and Gene Expression Omnibus databases were joined to verify the expression level of miR-452-5p in lung adenocarcinoma. Via several online prediction databases and bioinformatics software, pathway and network analyses of miR-452-5p target genes were performed to explore its prospective molecular mechanism. The expression of miR-452-5p in lung adenocarcinoma in house was significantly lower than that in adjacent tissues (p < 0.001). Additionally, the expression level of miR-452-5p was negatively correlated with several clinicopathological parameters including the tumor size (p = 0.014), lymph node metastasis (p = 0.032), and tumor-node-metastasis stage (p = 0.036). Data from The Cancer Genome Atlas also confirmed the low expression of miR-452 in lung adenocarcinoma (p < 0.001). Furthermore, reduced expression of miR-452-5p in lung adenocarcinoma (standard mean deviations = −0.393, 95% confidence interval: −0.774 to −0.011, p = 0.044) was validated by a meta-analysis. Five hub genes targeted by miR-452-5p, including SMAD family member 4, SMAD family member 2, cyclin-dependent kinase inhibitor 1B, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon, and tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta, were significantly enriched in the cell-cycle pathway. In conclusion, low expression of miR-452-5p tends to play an essential role in lung adenocarcinoma. Bioinformatics analysis might be beneficial to reveal the potential mechanism of miR-452-5p in lung adenocarcinoma.

show abstract

MiR-133a is downregulated in non-small cell lung cancer: a study of clinical significance

Cited by 33 publications

References 35 publications

Clinical value of miR-145-5p in NSCLC and potential molecular mechanism exploration: A retrospective study based on GEO, qRT-PCR, and TCGA data

Clinical value of miR-145-5p in NSCLC and potential molecular mechanism exploration: A retrospective study based on GEO, qRT-PCR, and TCGA data

The role of microRNA in metastatic processes of non-small cell lung carcinoma

Clinical value of miR-452-5p expression in lung adenocarcinoma: A retrospective quantitative real-time polymerase chain reaction study and verification based on The Cancer Genome Atlas and Gene Expression Omnibus databases

Contact Info

Product

Resources

About